BioNTech SE (BNTX) Gets a Buy from Morgan Stanley
TipRanks (Mon, 2-Feb 8:57 AM ET)
BioNTech and Bristol-Myers Squibb Advance Pumitamig Trial in Aggressive Brain Cancer
TipRanks (Fri, 30-Jan 11:33 AM ET)
Wall Street Analysts Are Bullish on Top Healthcare Picks
TipRanks (Fri, 30-Jan 6:40 AM ET)
Goldman Sachs Picks 2 Stocks That Let Investors Buy the Dip or Ride the Momentum
TipRanks (Fri, 30-Jan 6:09 AM ET)
BioNTech Elevates Global Talent Strategy with Kylie Jimenez Appointment as Chief People Officer
Market Chameleon (Wed, 28-Jan 4:08 AM ET)
BioNTech Announces Appointment of Kylie Jimenez to Management Board as Chief People Officer
Globe Newswire (Wed, 28-Jan 8:00 AM ET)
The $185B Cancer Surge: Why the FDA's Fast-Track Pivot is Scaling a New Immunotherapy Era
Globe Newswire (Wed, 14-Jan 10:40 AM ET)
Globe Newswire (Mon, 12-Jan 6:45 AM ET)
Globe Newswire (Thu, 18-Dec 4:45 AM ET)
BioNTech is a Germany-based biotechnology company that focuses on developing cancer therapeutics, including individualized immunotherapy, as well as vaccines for infectious diseases, including covid. The company's oncology pipeline contains several classes of drugs, including mRNA-based drugs to encode antigens, neoantigens, cytokines, and antibodies; cell therapies; bispecific antibodies; and antibody-drug conjugates, or ADCs. Comirnaty, its Pfizer-partnered covid vaccine, is its first commercialized product.
Biontech Se - American Depositary Shares trades on the NASDAQ stock market under the symbol BNTX.
As of February 3, 2026, BNTX stock price declined to $108.25 with 897,965 million shares trading.
BNTX has a beta of 0.93, meaning it tends to be less sensitive to market movements. BNTX has a correlation of 0.15 to the broad based SPY ETF.
BNTX has a market cap of $26.02 billion. This is considered a Large Cap stock.
Last quarter Biontech Se - American Depositary Shares reported $2 billion in Revenue and -$.14 earnings per share. This beat revenue expectation by $586 million and missed earnings estimates by -$.89.
In the last 3 years, BNTX traded as high as $147.66 and as low as $76.53.
The top ETF exchange traded funds that BNTX belongs to (by Net Assets): FBT, IBB, FNDF, TCAF, SPDW.
BNTX has underperformed the market in the last year with a price return of -12.5% while the SPY ETF gained +15.8%. However, in the short term, BNTX had mixed performance relative to the market. It has outperformed in the last 3 months, returning +4.2% vs +1.4% return in SPY. But in the last 2 weeks, BNTX shares have been beat by the market, returning -0.7% compared to an SPY return of -0.3%.
BNTX support price is $105.89 and resistance is $111.87 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that BNTX shares will trade within this expected range on the day.